519 related articles for article (PubMed ID: 17976313)
1. HDAC inhibitors: a potential new category of anti-tumor agents.
Pan LN; Lu J; Huang B
Cell Mol Immunol; 2007 Oct; 4(5):337-43. PubMed ID: 17976313
[TBL] [Abstract][Full Text] [Related]
2. Development of histone deacetylase inhibitors for cancer treatment.
Marchion D; Münster P
Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
[TBL] [Abstract][Full Text] [Related]
3. HDAC inhibitors for the treatment of cancer.
Secrist JP; Zhou X; Richon VM
Curr Opin Investig Drugs; 2003 Dec; 4(12):1422-7. PubMed ID: 14763127
[TBL] [Abstract][Full Text] [Related]
4. Anticancer activities of histone deacetylase inhibitors.
Bolden JE; Peart MJ; Johnstone RW
Nat Rev Drug Discov; 2006 Sep; 5(9):769-84. PubMed ID: 16955068
[TBL] [Abstract][Full Text] [Related]
5. Protein deacetylases: enzymes with functional diversity as novel therapeutic targets.
Yoshida M; Shimazu T; Matsuyama A
Prog Cell Cycle Res; 2003; 5():269-78. PubMed ID: 14593721
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment.
Weidle UH; Grossmann A
Anticancer Res; 2000; 20(3A):1471-85. PubMed ID: 10928059
[TBL] [Abstract][Full Text] [Related]
7. Role of histone deacetylase inhibitors in the treatment of cancer (Review).
Mei S; Ho AD; Mahlknecht U
Int J Oncol; 2004 Dec; 25(6):1509-19. PubMed ID: 15547685
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
Carew JS; Giles FJ; Nawrocki ST
Cancer Lett; 2008 Sep; 269(1):7-17. PubMed ID: 18462867
[TBL] [Abstract][Full Text] [Related]
9. Acetylation of proteins as novel target for antitumor therapy: review article.
Di Gennaro E; Bruzzese F; Caraglia M; Abruzzese A; Budillon A
Amino Acids; 2004 Jul; 26(4):435-41. PubMed ID: 15290351
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
Mai A; Massa S; Rotili D; Cerbara I; Valente S; Pezzi R; Simeoni S; Ragno R
Med Res Rev; 2005 May; 25(3):261-309. PubMed ID: 15717297
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic therapy in cancer: molecular background and clinical development of histone deacetylase and DNA methyltransferase inhibitors.
Schneider-Stock R; Ocker M
IDrugs; 2007 Aug; 10(8):557-61. PubMed ID: 17665331
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylation as a target for radiosensitization.
Cerna D; Camphausen K; Tofilon PJ
Curr Top Dev Biol; 2006; 73():173-204. PubMed ID: 16782459
[TBL] [Abstract][Full Text] [Related]
13. HDAC family: What are the cancer relevant targets?
Witt O; Deubzer HE; Milde T; Oehme I
Cancer Lett; 2009 May; 277(1):8-21. PubMed ID: 18824292
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic therapy using the histone deacetylase inhibitor for increasing therapeutic gain in oral cancer: prevention of radiation-induced oral mucositis and inhibition of chemical-induced oral carcinogenesis.
Chung YL; Lee MY; Pui NN
Carcinogenesis; 2009 Aug; 30(8):1387-97. PubMed ID: 19351790
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
16. HDAC inhibitors: clinical update and mechanism-based potential.
Glaser KB
Biochem Pharmacol; 2007 Sep; 74(5):659-71. PubMed ID: 17498667
[TBL] [Abstract][Full Text] [Related]
17. [Assay for inhibitory activity of histone deacetylase].
Yoshida M
Gan To Kagaku Ryoho; 2004 Apr; 31(4):507-11. PubMed ID: 15114691
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylases and cancer: causes and therapies.
Marks P; Rifkind RA; Richon VM; Breslow R; Miller T; Kelly WK
Nat Rev Cancer; 2001 Dec; 1(3):194-202. PubMed ID: 11902574
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors: molecular mechanisms of action.
Xu WS; Parmigiani RB; Marks PA
Oncogene; 2007 Aug; 26(37):5541-52. PubMed ID: 17694093
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitors, anticancerous mechanism and therapy for gastrointestinal cancers.
Fang JY
J Gastroenterol Hepatol; 2005 Jul; 20(7):988-94. PubMed ID: 15955204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]